Pharming Group N.V..’s leniolisib has impressed in a Phase II/II APDS trial, sparking plans for US and EU regulatory filings in the second quarter of this year and encouraging the firm to delve into the Japanese market.
Leniolisib met the endpoints in a pivotal activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) study in patients aged over 12...